**TERMS OF DEVELOPMENT
of clinical manifestations of adverse events at using vaccines, tuberculin**

|  |  |
| --- | --- |
| Vaccines, tuberculin | Terms of development of clinical manifestations of adverse events at using vaccines, tuberculin |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 |
| DTP, DT, Td | <72 h | <48 h, to 7 days | < 7 days | < 48 h | - | <72 h | - | - | - | - | <14 days | <48 h | <72 h | - | <48 h | 7-14 days | 2-3 days | - | - | - | - | - |
| DTaP, combined vaccines based on DTaP | <48 h | <72 h, to7 days | <7 days | <48 h | - | <72 h | unknown | unknown | - | unknown | <14 days | <48 h | <48 h | - | <48 h | 7-14 days | 2-3 days | - | - | - | - | - |
| Vaccines for prevention of measles, mumps, rubella (MMR) | 4-10 days | 24 h to 7 days | 4-10 days | 4-10 days | 7-10 days | unknown | 6-15 days | 4-10 days | 7-10 days | 12-25 days | <14 days | <48 h. | <72 h | - | 6-12 days | - | - | - | - | - | - | - |
| BCG | unknown | specific reactions | - | unknown | - | - | - | - | - | - | - | <48 h | unknown | - | - | - | unknown | 1,5-6 m | 1,5-6 m | 1-12 m | 5-12m | 1-24 m |
| OPV | unknown | - | - | <72 h | - | <72 h | - | unknown | - | - | - | - | unknown | 4-30 days | - | - | unknown | - | - | - | - | - |
| IPV | <48 h | <48 h to 7 days | unknown | <48 h | - | unknown | - | <48 h | - | - | <14 days | <48 h | <72 h | - | unknown | - | unknown | - | - | - | - | - |
| Vaccines for prevention of hepatitis B  | <72 h | <48 h to 7 days | unknown | <72 h | - | <5 days | <72 h. | <72 h | - | - | <14 days | <48 h | <72 h | - | <48 h | <72 h | unknown | - | - | - | - | - |
| Haemophillus influenza type B | <72 h | <48 h to 7 days | - | <48 h | <72h | <72 h | - | <72 h | - | - | <14 days | <48 h | <72 h | - | <48 h | un-known | 2-3 days | - | - | - | - | - |
| Tuberculin | <48 h | Pain in the injection site or discomfort, irritation or swelling <72 h | - | Headache <48 h | - | - | - | - | - | - | - | - | unknown | - | - | - | - | - | - | - | - | - |